As the first Integrated Development and Manufacturing Organization (IDMO), Cellares takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. Our flagship technologies—the Cell Shuttle™, an automated manufacturing platform, and Cell Q™, a quality control workcell—power global Smart Factories that provide revolutionary cost savings and throughput advantages compared to traditional CDMOs.

Biotech companies leveraging Cellares’ IDMO™ manufacturing services can achieve up to a 50% reduction in batch prices, eliminate cleanroom fees for clinical manufacturing, and recoup tech translation costs in as few as 28 batches. By the time Phases 1, 2, and 3 have been completed, biotech companies can ultimately realize up to 10x the initial tech translation costs, extending cash runways by as much as two years.

With a reservation model that is flexible and aligned to success & resources, biotech companies can reserve dedicated capacity only when needed and while still benefiting from immediate economies of scale, even at lower volumes.

Cellares' approved designation under the FDA's Advanced Manufacturing Technologies (AMT) Designation Program unlocks priority FDA pathways, giving biotechs faster, more frequent interactions with regulators and a dedicated AMT Lead to accelerate IND and BLA approvals. De-risk the path to commercialization with predictable costs, scalable infrastructure, and regulatory acceleration.